Medicare said this week it will pay for two cancer treatments with hefty price tags -- and lingering questions: Avastin, the controversial drug shot down by an Food and Drug Administration panel on ...

NEW YORK (Reuters) - In Dendreon Corp's most important clinical trial for the controversial cancer therapy Provenge, researchers analyzed some of the data differently from how the company told U.S.

The influential National Comprehensive Cancer Network (NCCN, www.nccn.org) has given Provenge its top rating. Although Medicare often follows NCCN guidelines, “In this climate I’m not sure that [NCCN] ...

Sid Thompson no longer suffers from constant pain. He goes out to dinner weekly with his granddaughters and regularly has lunch with golfing buddies. The 70-year-old runs errands with his wife, ...

Dendreon Corp. said its experimental drug Provenge reduced the risk of death 20 percent in a study of men with advanced prostate cancer, sending the company's stock up the most in more than a year.

NEW YORK, March 30 (Reuters) - Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy. Doctors who raised doubts about it received death threats. Health regulators ...